Trials / Completed
CompletedNCT02515227
Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab
A Trial to Evaluate the Safety, Immunogenicity, and Clinical Activity of a Helper Peptide Vaccine Plus PD-1 Blockade
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Craig L Slingluff, Jr · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates whether it is safe to administer a peptide vaccine in combination with pembrolizumab. This study will also evaluate the effects of the combination of the peptide vaccine and pembrolizumab on the immune system. The investigators will monitor these effects by performing tests in the laboratory on participants' blood, a lymph node, and tumor samples.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | 6MHP | 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides |
| DRUG | Pembrolizumab | Humanized monoclonal antibody (mAb) specific for PD-1. |
Timeline
- Start date
- 2016-10-06
- Primary completion
- 2020-03-14
- Completion
- 2020-03-14
- First posted
- 2015-08-04
- Last updated
- 2023-08-25
- Results posted
- 2023-08-25
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02515227. Inclusion in this directory is not an endorsement.